Bayer

Olivier Brandicourt appointed chairman of Bayer HealthCare

Tuesday, October 1, 2013 11:00 AM

Olivier Brandicourt has been appointed chairman of the board of management of Bayer HealthCare and member of the Bayer executive council effective Nov. 1. Since March, professor Wolfgang Plischke has led Bayer HealthCare on an interim basis in addition to his existing duties as a Bayer board member.

More... »

DKSH, Bayer expand collaboration to Singapore

Monday, September 16, 2013 03:09 PM

DKSH Business Unit Healthcare, a market expansion services provider that partners with healthcare companies seeking to grow their business in Asia, is collaborating with Bayer Thai to provide services for Bayer's products in Singapore.

More... »

Bayer, Broad Institute collaborate for cancer therapy

Wednesday, September 11, 2013 01:23 PM

Bayer HealthCare is collaborating with the Broad Institute in Cambridge, Mass. for oncogenomics and drug discovery. The Broad Institute, a nonprofit biomedical research institutes, brings together scientists from Harvard, MIT and Harvard-affiliated hospitals, and has experience in genomics, cancer, chemical biology and drug discovery. They intend to jointly discover and develop therapeutic agents that selectively target cancer genome alterations over a period of five years.

More... »

Amgen to acquire Onyx Pharmaceuticals

Monday, August 26, 2013 12:07 PM

Amgen will acquire San Francisco, Calif.-based Onyx Pharmaceuticals, purchasing all of the outstanding shares of Onyx for $125 per share in cash, for a total purchase price of $10.4 billion, or $9.7 billion net of estimated Onyx cash. The boards of both companies have approved the transaction.

More... »

Seattle Genetics, Bayer in ADC collaboration

Wednesday, June 26, 2013 03:13 PM

Biotech Seattle Genetics has entered into an antibody-drug conjugate (ADC) collaboration with Bayer HealthCare. Bayer will pay upfront and option exercise fees of up to $20 million for worldwide rights to utilize Seattle Genetics' auristatin-based ADC technology with antibodies to several oncology targets. Seattle Genetics also is eligible to receive up to $500 million in potential milestone payments, as well as royalties on worldwide net sales of any resulting products under the multi-target collaboration. Bayer is responsible for research, product development, manufacturing and commercialization of all products. 

More... »

Johannes Schubmehl appointed CIO of Bayer HealthCare

Friday, May 24, 2013 11:31 AM

Bayer HealthCare, a global healthcare company, has appointed Johannes Schubmehl as chief information officer (CIO). Schubmehl succeeds Matthias Moritz, who had left the company at the end of March.

More... »

FDA approves Bayer’s Xofigo for advanced prostate cancer

Thursday, May 23, 2013 08:00 AM

The FDA has approved Bayer Pharmaceuticals’ Xofigo (radium Ra 223 dichloride) to treat males with symptomatic late-stage metastatic castration-resistant prostate cancer that has spread to bones but not to other organs. It is intended for men whose cancer has spread after receiving medical or surgical therapy to lower testosterone.

More... »

Bayer to acquire Steigerwald Arzneimittelwerk

Friday, May 17, 2013 11:56 AM

Bayer has signed an agreement to acquire 100% of the shares of Steigerwald Arzneimittelwerk, a Darmstadt, Germany-based privately held pharmaceutical company specializing in pharmacy-only herbal medicines.

More... »

Bayer to acquire Conceptus

Monday, April 29, 2013 10:50 AM

Bayer HealthCare has signed a merger agreement with Conceptus, a Mountain View, Calif.-based developer of the Essure procedure, a non-surgical permanent birth control method.

More... »

Janssen launches global cardiovascular research program, five new studies

Friday, March 8, 2013 10:47 AM

Janssen Research & Development has launched EXPLORER, a comprehensive, global research program for XARELTO (rivaroxaban), an oral anticoagulant. The program includes studies that will evaluate XARELTO for investigational use in patients with chronic heart failure and in those with coronary artery disease or peripheral artery disease.

More... »